In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Game’s Up, Pharma: The New Drug Pricing Dynamics

Executive Summary

Hepatitis C drugs may have provided the spark, but cost-pressured payors, empowered consumers, and at-risk providers are adding fuel to the drug pricing fire. The game may be up for pharma firms that try to push prices out of line with perceived value, potential patient volumes, and affordability.

Advertisement

Related Content

A Road Map To Strategic Drug Pricing
European Notebook: Drug Pricing Collaborations; Biosimilar Switching; Scientific Advice
Role Of Cost And Evidence In Value-Based Purchasing Highlighted By Zaltrap Price Adjustment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel